Cargando…
Pharmacological Mechanisms Involved in Sensory Gating Disruption Induced by (±)-3,4-Methylene- Dioxymethamphetamine (MDMA): Relevance to Schizophrenia
Sensory gating deficits have been demonstrated in schizophrenia, but the mechanisms involved remain unclear. In the present study, we used disruption of paired-pulse gating of evoked potentials in rats by the administration of (±)-3,4-methylene-dioxymethamphetamine (MDMA) to study serotonergic and d...
Autores principales: | Lee, Jaime, Thwaites, Shane, Gogos, Andrea, van den Buuse, Maarten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016806/ https://www.ncbi.nlm.nih.gov/pubmed/31941052 http://dx.doi.org/10.3390/brainsci10010044 |
Ejemplares similares
-
CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals
por: Schmid, Yasmin, et al.
Publicado: (2016) -
MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology
por: Sáez-Briones, P., et al.
Publicado: (2013) -
3,4-methylenedioxymethamphetamine (MDMA): current perspectives
por: Meyer, Jerrold S
Publicado: (2013) -
MDMA for the Treatment of Negative Symptoms in Schizophrenia
por: Arnovitz, Mitchell D., et al.
Publicado: (2022) -
Detección de 3,4- metilenodioximetanfetamina (MDMA) en saliva
por: Denis Rodríguez, Edmundo, et al.
Publicado: (2016)